Melanie K. Shadoan

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

Brian Zambrowicz, J Freiman, Phil Brown et al. · Clinical Pharmacology & Therapeutics · 2012 · 235 citations · Full text

Mice Heterozygous for a Defect in Mitochondrial Trifunctional Protein Develop Hepatic Steatosis and Insulin Resistance

Jamal A. Ibdah, Peter S. Perlegas, Yiwen Zhao et al. · Gastroenterology · 2005 · 184 citations

Insulin Resistance, Metabolic Syndrome, Mice Heterozygous +11

LX4211 Increases Serum Glucagon-Like Peptide 1 and Peptide YY Levels by Reducing Sodium/Glucose Cotransporter 1 (SGLT1)–Mediated Absorption of Intestinal Glucose

David R. Powell, Melinda Smith, Jennifer Greer et al. · Journal of Pharmacology and Experimental Therapeutics · 2013 · 181 citations

Deletion of the mouse <i>Slc30a8</i> gene encoding zinc transporter-8 results in impaired insulin secretion

Lynley D. Pound, Suparna A. Sarkar, Richard K.P. Benninger et al. · Biochemical Journal · 2009 · 172 citations · Full text

Improved glycemic control in mice lacking Sglt1 and Sglt2

David R. Powell, Christopher M. DaCosta, Jason Gay et al. · American Journal of Physiology-Endocrinology and Metabolism · 2012 · 157 citations

Metabolic Syndrome, Glucose Tolerance, Energy Homeostasis +14